ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Announcing ALK Positive ClinWiki, A Better Way to Search for Clinical Trials
The main register of worldwide clinical trials is ClinicalTrials.gov, which has a search function. But searching for “ALK lung cancer” on ClinicalTrials.gov is a frustrating exercise. Oddly, you will be directed to many studies that exclude ALK lung cancer. The ALK lung cancer trials in ClinicalTrials.gov are not sorted by line of treatment, so it…
-
The latest from ALK Positive Inc.
ALK Positive, Inc. became a registered 501c3 (nonprofit) organization in March 2021. Both the ALK Positive Board of Directors and the ALK Positive Committees are comprised of volunteer members from the ALK Positive Support Group, all ALK-positive patients or caregivers themselves. The Board and Committees are all working together to improve the life expectancy and…
-
Dr. Ou at ALKtALK
Dr. Ignatius Sai-Hong Ou – Professor in Hematology-Oncology, Medical Oncology University of California, Irvine Editor-in-Chief of Lung Cancer: Targets and Therapy Associate Editor of Journal of Thoracic Oncology Question: We want to know a little about you. What brought you to study ALK? I was just a young aimless attending (MD) in 2007. I was…
-
Fundraising Guide and Tips for Lung Cancer Awareness Month
About Lung Cancer Awareness MonthNovember is Lung Cancer Awareness Month (LCAM) — an excellent time of year to raise awareness and funds for research. LCAM is ALK Positive’s largest fundraising campaign of the year. We’ve set a goal to raise $1,000,000 in 2021. A huge thank you to the generous match donors who have pledged…
-
International Ambassadors Survey- ALK Life Study
An informal survey was conducted with our ALK International Ambassadors, volunteers from various countries who are passionate about sharing their experiences with others. A total of 22 countries were represented in this survey. In addition to the US, European nations were well represented, as were Australia and New Zealand. There was a notable lack of…
-
ALK-positive Clinical Trials are not just for people in the United States
If you are at diagnosis or at a juncture in treatment, an ALK-positive lung cancer clinical trial may help you receive state of the art treatment. Although many clinical trials for ALK-positive lung cancer have sites in the US, ALK Positives around the world have multiple clinical trial options. An exciting trial outside the US…
-
Are there any new Clinical Trials recruiting for ALK-positive lung cancer?
Clinical trials for more advanced ALK inhibitors, like the TPX-131 study recruiting in Australia and the US, are exciting because they improve on drugs we know work well for ALK-positive lung cancer. However most clinical trials of new ALK treatments in the US and Europe involve combination therapies, designed to overcome ALK inhibitor resistance. As…
-
Gilteritinib overcomes Lorlatinib resistance in ALK-rearranged cancer
by Mizuta et al. (Japan) A common problem we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two known mechanisms so far for resistance. One is for the cancer cells to activate an alternative bypass pathway such as EGFR, cMET, KRAS, or AXL to…